Mobile website
Archive > Volume 24 Issue 6 > 2017,24(6):575-580. DOI:10.3872/j.issn.1007-385X.2017.06.001 Prev Next
Expert Forum
Key problems and countermeasures of the immunotherapy for solid tumors
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
In recent years, great breakthrough progresses have been achieved in cancer immunotherapy, cytoimunotherapy with CART as a representative has achieved encouraging clinical efficacy in the treatment of hematologic tumors, immune checkpoint inhibitor, CTLA4 and PD1/PDL1 monoclonal antibodies, have been approved for clinical use in one after another. However, most of the patients with solid tumors did not get benefit from the immunotherapy. This paper summarized key problems that were difficult to resolve in the immunotherapy of solid tumors from aspects of screening individual noval antigen epitopes, maintaining viability of the immune cells , chemotaxis and invasion of the immunocytes, clinical treatment model, evaluation criterion and so on. And their coping strategies were described from the angle of clinical application.
Keywords:
Project Supported:
Project supported by National Natural Science Foundation of China（No.81672367)
Clc Number:
